共查询到17条相似文献,搜索用时 140 毫秒
1.
目的构建人乳头瘤病毒16型(HPV16)E7基因密码子优化后的原核表达系统,通过特异性抗体制备评价E7融合蛋白的免疫原性。方法人工合成优化后的HPV16 E7基因,利用特异引物扩增HPV16 E7基因。将E7基因连接至原核表达载体构建重组表达质粒pMAl-c2X-E7,转化至感受态细胞DE3后,经IPTG诱导,SDS-PAGE分析表达产物E7融合蛋白。纯化后的E7融合蛋白免疫动物,采用ELISA检测动物血清效价。结果 E7基因PCR产物的测序结果与优化后的目的基因序列比对一致。表达的E7融合蛋白经SDS-PAGE分析表明:在相对分子质量50 000处有特异性表达带,与预期相符。以E7融合蛋白制备的多克隆抗体其血清效价可达1∶64 000。结论成功构建的重组表达质粒pMAl-c2X-E7可有效表达MBP-E7融合蛋白,E7融合蛋白具有良好的免疫原性。 相似文献
2.
人乳头瘤病毒16型L1和L2基因表达产物的鉴定 总被引:1,自引:0,他引:1
目的:构建人乳头瘤病毒(human papillomavirus,HPV)16型晚期基因L1及L2的原核表达质粒,并验证目的蛋白的表达.方法:用限制性酶切及连接的方法构建原核表达质粒pET3a-16 L1和pET3a-16 L2,通过SDS-PAGE及Westen blot检测目的融合蛋白的表达.结果:在大肠菌中诱导表达的L1蛋白分子量约为57 KD,L2蛋白分子量约为90 KD.结论:该实验结果为HPV16型预防性基因工程亚单位疫苗的研制和诊断试剂的研究开发奠定了基础. 相似文献
3.
人乳头瘤病毒16型病毒样颗粒的制备及其免疫原性研究 总被引:1,自引:0,他引:1
利用PCR技术从HPV16阳性阴道分泌物标本中获得HPV16 L1基因片段,并将其插入表达载体pTO-T7中,构建重组表达质粒pTO-T7-HPV16-L1;以该重组质粒转化大肠杆菌ER2566并表达HPV16 L1蛋白;所表达的HPV16 L1蛋白经过硫酸铵沉淀、离子交换层析和疏水相互作用层析等纯化步骤后,HPV16 L1纯度达到98%以上,并可在体外装配为直径50nm的病毒样颗粒;动物免疫原性研究结果显示,该病毒样颗粒可诱导高滴度的针对HPV16的中和抗体。上述研究结果表明通过大肠杆菌表达系统制备的HPV16病毒样颗粒具有纯度高,与天然病毒颗粒形态高度相似的特点,并具有高度免疫原性,可以应用于HPV16病毒样颗粒的结构功能研究及HPV16疫苗研发等领域。 相似文献
4.
目的:研究CpG佐剂、弗氏佐剂、聚肌胞苷酸佐剂及左旋咪唑、西米替丁作为佐剂对人乳头瘤病毒16型L2E7E6融合蛋白在小鼠体内产生的免疫效果的影响。方法:以单独蛋白组、蛋白加各佐剂组分别肌肉注射免疫C57BL/6小鼠,检测不同佐剂诱发小鼠产生的体液免疫和细胞免疫应答水平,并观察其对小鼠肿瘤生长的抑制作用。结果:各免疫组均能检测到高滴度的抗L2、E7、E6蛋白IgG抗体(以IgG1为主),其中弗氏佐剂能显著提高E6蛋白的IgG和IgG1抗体水平和E7蛋白的IgG1抗体水平(P<0.05),CpG佐剂明显提高了E7蛋白的IgG2a抗体水平(P<0.01);而西米替丁佐剂则降低了E7抗原的IgG抗体水平(P<0.05);同时可以检测到CpG佐剂组能诱发小鼠产生针对E7、E6较强的细胞免疫反应,且能抑制70%的荷瘤小鼠肿瘤生长;此外弗氏佐剂与聚肌胞苷酸佐剂可产生较弱的针对E7肽的细胞免疫反应,能延缓荷瘤小鼠肿瘤形成时间,与单纯蛋白组相比差异显著(P<0.05)。结论:CpG佐剂、弗氏佐剂和聚肌胞苷酸佐剂都能提高人乳头瘤病毒16型L2E7E6融合蛋白的细胞免疫反应水平和抑制肿瘤生长能力,其中CpG佐剂效果较好,为促进该蛋白作为疫苗的研发提供了实验依据。 相似文献
5.
人乳头瘤病毒16型-L1真核表达质粒的构建和表达以及实验动物对裸DNA的免疫反应 总被引:2,自引:0,他引:2
Recombinant plasmid pcDNA-L1 was constructed by inserting HPV16-L1 gene fragment into eukaryotic expression plasmid pcDNA3.1. pcDNA-L1 was transfected into mammalian cells Cos-7 and the expression of HPV16-L1 protein was testified by immunohistochemistry(IHC). Then the recombinant plasmid was directly injected into the quadriceps muscle of BALB/c mice. Antibodies against HPV16-L1 in the immunized mice were positively detected by immunodot and IHC at 28 and 41 days after the last immunization. 相似文献
6.
鉴定人乳头瘤病毒16型早期蛋白7(HPV16E7)过表达细胞及其迁移效应的影响,为后续基于HPV16E7靶向分子作用机制的研究奠定工作基础.脂质体转染法将本室保存的pcDNA3.1-HPV16E7重组真核表达质粒分别转染人胚肾293T细胞(HPV16型DNA阴性)、宫颈癌SiHa细胞株(HPV16 DNA阳性),转染48 h后收集细胞,提取RNA,RT-PCR扩增相应的目的基因,Western Blotting和间接免疫荧光实验检测HPV16E7目的蛋白在细胞中的表达.转染24h的细胞进行细胞划痕和Transwell实验,检测过表达细胞迁移行为的变化.RT-PCR结果显示:分别从E7质粒转染的293T、SiHa细胞的cDNA中,均可扩增到250 bp的目的条带;Western Blotting分析结果显示:以HPV16E7单克隆抗体为检测抗体,转染细胞的裂解液中均能在相对分子质量(Mr)约为15 000处出现特异性目的条带;间接免疫荧光结果显示:转染细胞中均能检测到目的绿色荧光,且分布于胞浆及细胞核周围;细胞划痕和Transwell实验结果显示:转染E7细胞的迁移效应显著提高.本研究证实了 HPV16E7转染细胞后可成功表达,且过表达细胞明显促进了细胞迁移行为,为后续基于HPV16E7迁移相关分子机制及靶向干预等研究奠定了前期工作基础. 相似文献
7.
目的:构建pET-42a(+)-HPV58E6E7原核表达质粒,诱导表达人乳头瘤病毒(HPV)58型E6E7融合蛋白。方法:采用PCR方法扩增出HPV58 E6E7融合基因的全长序列,利用DNA重组技术将其定向插入原核表达载体pET-42a(+)中,构建pET-42a(+)-HPV58E6E7原核表达质粒,用限制性内切酶酶切和核酸序列检测对重组质粒进行鉴定;将其转入宿主菌大肠杆菌BL21进行诱导以表达HPV58E6E7融合蛋白,并用谷胱甘肽琼脂糖树脂纯化回收HPV58E6E7融合蛋白,用SDS-PAGE及Western印迹鉴定表达蛋白的相对分子质量及抗原性。结果:PCR、限制性内切酶酶切和核酸序列检测证实重组质粒中插入的目的基因大小、方向正确;HPV58E6E7融合蛋白得到高效原核表达及纯化,表达蛋白的分子大小正确,抗原性良好。结论:pET-42a(+)-HPV58E6E7原核表达质粒构建成功,HPV58E6E7融合蛋白得到高效表达及有效纯化,为检测HPV58型治疗性疫苗的免疫效果提供了抗原。 相似文献
8.
采用分子克隆技术,构建E7变异株重组质粒[pcDNA3.1-(by)E7]和E7标准株重组质粒【pcDNA3.1.(ys)-E7】,并将两种质粒分别皮下免疫Balb/c小鼠,免疫后于不同时间提取小鼠血清和制备脾淋巴细胞悬液,分别用ELISA法和MTT比色法检测特异性抗体和特异性淋巴细胞增殖反应。基因免疫后,ELISA法显示,HPVl6E7变异株和标准株均能诱导特异性抗E7抗体;MTTT比色法显示,E7标准株免疫组脾淋巴细胞在体外受到变异株E7蛋白的再次刺激后出现特异性淋巴细胞增殖反应,变异株E7免疫组脾淋巴细胞经过同样处理后,出现非特异性淋巴细胞增殖反应。结果表明HPV16E7变异株能诱导特异性体液免疫应答而不能诱导特异性细胞免疫应答,HPVl6E7变异株无论在结构还是免疫原性上均与标准株有差异。由此推测,HPV16E7变异可能导致其逃逸机体自然感染或疫苗诱导的免疫应答。用基因免疫方法研究E7变异株免疫原性也为其它不能或难以进行体外培养的病毒变异研究提供借鉴。 相似文献
9.
目的 HPV的某些型别尤其是HPV16 ,18型感染与宫颈癌的发生有密切的关系。宫颈癌在全球妇女癌症死亡原因中居第二位。在发展中国家 ,宫颈癌在妇女癌症死因中列第一位。尽管早期宫颈癌患者放疗及手术治疗效果较好 ,但对中晚期宫颈癌患者治疗效果却很差。因而 ,采取有效的措施预防HPV感染对于宫颈癌防治工作无疑是非常必要的。在对乳头瘤病毒结构和功能的研究中发现 ,以L1和L2为保护性抗原构建的疫苗株很可能在预防HPV感染及其引起的恶性肿瘤方面发挥重要作用。目前国际上常通过原核和真核表达系统获得L1和L2蛋白。本实验拟通过原核表… 相似文献
10.
为了构建HPV16型晚期蛋白重组杆状病毒,并使其在昆虫细胞中获得高效表达.首先构建2株重组杆状病毒转移质粒,分别携带人乳头瘤病毒晚期基因L1及L1和L2,再用线性化的杆状病毒DNA与该重组杆状病毒转移质粒共转染sf9昆虫细胞进行同源重组,获得2株重组杆状病毒.经鉴定该重组病毒中有目的基因存在且可表达所编码的L1或L2晚期蛋白.结果表明HPV16型晚期蛋白在昆虫细胞中获得成功表达,为HPV16型预防性基因工程亚单位疫苗的研制和诊断试剂的研究开发奠定了基础. 相似文献
11.
人乳头瘤病毒16亚型L1蛋白在多形汉逊酵母中的优化表达 总被引:1,自引:0,他引:1
为了实现人乳头瘤病毒(Humanpa pillomavirus,HPV)16亚型衣壳蛋白L1在多形汉逊酵母(Hansenula polymorpha)中的高效表达,根据L1蛋白的氨基酸序列及多形汉逊酵母的密码子偏爱性,对L1蛋白的编码序列进行优化设计,合成了完整的编码序列,命名为HPV16L1。以甲醇诱导型启动子MOXp和终止子AOXTT为表达调控元件,以尿嘧啶合成相关基因URA3为筛选标记,构建了HPV16L1的重组表达质粒pYMOXU-HPV16。用SacII酶切质粒pYMOXU-HPV16使其线性化,电转化多形汉逊酵母菌株H-ura3,依据营养缺陷互补筛选重组菌株。通过PCR扩增及HPV16L1蛋白表达量分析表明已获得稳定高表达L1蛋白的重组汉逊酵母菌株HP-U-16L。摇瓶发酵条件的初步优化表明,以YPM(pH7.0)为基础培养基进行诱导培养,控制接种量使初始培养液OD600为1.0,每隔12h补加甲醇至终浓度为1%(V/V),37oC、200r/min条件下诱导培养72h后,HPV16L1蛋白的最高表达量为78.6mg/L。本研究为多形汉逊酵母源HPV16L1疫苗的研制奠定了基础。 相似文献
12.
Human papillomavirus 16 (HPV16) E6E7 pre-mRNA is bicistronic and has an intron in the E6 coding region with one 5' splice site and two alternative 3' splice sites, which produce E6(*)I and E6(*)II, respectively. If this intron remains unspliced, the resulting E6E7 mRNA expresses oncogenic E6. We found for the first time that the E6E7 pre-mRNA was efficiently spliced in vitro only when capped and that cellular cap-binding factors were involved in the splicing. The cap-dependent splicing of the E6E7 pre-mRNA was extremely efficient in cervical cancer-derived cells, producing mostly E6(*)I, but inefficient in cells transfected with a common retrovirus expression vector, pLXSN16E6E7, due to the large size of this vector's exon 1. Further studies showed that efficient splicing of the E6E7 pre-mRNA depends on the distance of the cap-proximal intron from the RNA 5' cap, with an optimal distance of less than 307nt in order to facilitate better association of U1 small nuclear RNA with the intron 5' splice site. The same was true for splicing of human beta-globin RNA. Splicing of the E6E7 RNA provided more E7 RNA templates and promoted E7 translation, whereas a lack of RNA splicing produced a low level of E7 translation. Together, our data indicate that the distance between the RNA 5' cap and cap-proximal intron is rate limiting for RNA splicing. HPV16 E6E7 pre-mRNA takes advantage of its small cap-proximal exon to confer efficient splicing for better E7 expression. 相似文献
13.
Gomez-Gutierrez JG Elpek KG Montes de Oca-Luna R Shirwan H Sam Zhou H McMasters KM 《Cancer immunology, immunotherapy : CII》2007,56(7):997-1007
BACKGROUND: Cervical cancer remains a leading cause of cancer-related mortality in women, particularly in developing countries. The causal association between genital human papilloma virus (HPV) infection and cervical cancer has been firmly established, and the oncogenic potential of certain HPV types has been clearly demonstrated. Vaccines targeting the oncogenic proteins, E6 and E7 of HPV-16 and -18 are the focus of current vaccine development. Previous studies have shown that calreticulin (CRT) enhances the MHC class I presentation of linked peptide/protein and may serve as an effective vaccination strategy for antigen-specific cancer treatment. METHODS: Two replication-deficient adenoviruses, one expressing HPV-16 E7 (Ad-E7) and the other expressing CRT linked to E7 (Ad-CRT/E7), were assessed for their ability to induce cellular immune response and tested for prophylactic and therapeutic effects in an E7-expressing mouse tumor model. RESULTS: Vaccination with Ad-CRT/E7 led to a dramatic increase in E7-specific T cell proliferation, interferon (IFN)-gamma-secretion, and cytotoxic activity. Immunization of mice with Ad-CRT/E7 was effective in preventing E7-expressing tumor growth, as well as eradicating established tumors with long-term immunological memory. CONCLUSION: Vaccination with an adenoviral vector expressing CRT-E7 fusion protein represents an effective strategy for immunotherapy of cervical cancer in rodents, with possible therapeutic potential in clinical settings. 相似文献
14.
Pil-Soo Seo Sun-Yeon Heo Eun Jong Han Jeong-Woo Seo Shin-Je Ghim Chul Ho Kim 《Biotechnology and Bioprocess Engineering》2009,14(2):168-174
The human papillomavirus (HPV) 18 L1 gene, which encodes the L1 major capsid protein, was isolated from a female patient in
Pusan, Korea Republic and was cloned into pGEX-4T-1 vector. The HPV-18L1 gene was expressed in Escherichia coli as a fusion protein with a glutathione-S-transferase (GST) tag. The soluble recombinant fusion protein, GST-18 L1 fusion,
was isolated to high purity. HPV-18 L1 was purified from the GST-18 L1 fusant after biotinylated thrombin cleavage, and then
the treated thrombin was removed serially using streptavidin conjugated resin. The purified HPV-18 L1 was confirmed by western
blotting using a rabbit anti-denatured papillomavirus polyclonal antibody. The virus-like particles (VLP) from the purified
full-length 18 L1 protein without any extra amino acid sequences was observed through the analysis of the electron microscope.
This is the first study to report the expression and purification of HPV-18 L1 in E. coli. This expression and purification system offers a simple method of expressing and purifying HPV L1 protein, and could potentially
be an effective route for the development and manufacturing of highly purified HPV-18 L1-based cervical cancer vaccines. 相似文献
15.
Construction of prophylactic human papillomavirus type 16 L1 capsid protein vaccine delivered by live attenuated Shigella flexneri strain sh42 总被引:1,自引:0,他引:1
Yang XF Qu XZ Wang K Zheng J Si LS Dong XP Wang YL 《Acta biochimica et biophysica Sinica》2005,37(11):743-750
To express human papillomavirus (HPV) L 1 capsid protein in the recombinant strain of Shigella and study the potential of a live attenuated Shigella-based HPV prophylactic vaccine in preventing HPV infection, the icsA/virG fragment of Shigella-based prokaryotic expression plasmid pHS3199 was constructed. HPV type 16 L1 (HPV16L1) gene was inserted into plasmid pHS3199 to form the pHS3199-HPV16L1 construct, and pHS3199-HPV 16L1 was electroporated into a live attenuated Shigella strain sh42. Western blotting analysis showed that HPV 16L 1 could be expressed stably in the recombinant strain sh42-HPV 16L 1. Sereny test results were negative, which showed that the sh42-HPV16L1 lost virulence. However, the attenuated recombinant strain partially maintained the invasive property as indicated by the HeLa cell infection assay. Specific IgG, IgA antibody against HPV16L1 virus-like particles (VLPs) were detected in the sera, intestinal lavage and vaginal lavage from animals immunized by sh42-HPV 16L1. The number of antibodysecreting cells in the spleen and draining lymph nodes were increased significantly compared with the control group. Sera from immunized animals inhibited mufine hemagglutination induced by HPV 16L1 VLPs, which indicated that the candidate vaccine could stimulate an efficient immune response in guinea pig's mucosal sites. This may be an effective strategy for the development of an HPV prophylactic oral vaccine. 相似文献
16.
Enhancement of immunotherapeutic effects of HPV16E7 on cervical cancer by fusion with CTLA4 extracellular region 总被引:2,自引:0,他引:2
Yi Zheng Yijuan Zhang Yuandong Ma Jun Wan Chaofan Shi Laiqiang Huang 《Journal of microbiology (Seoul, Korea)》2008,46(6):728-736
Cervical cancer is caused by infection by high-risk human papillomavirus (HPV), especially HPV16. Limitations in current treatments
of cervical cancers call for the development of new and improved immunotherapies. This study aims at investigating the efficacy
of a novel vaccine consisting of modified HPV 16E7 fused with human cytotoxic T-lymphocyte antigen 4 (CTLA4). The regions
in HPV16 E7 gene associated with its transformation and CTL-enhanced response were modified; the resultant HPV16mE7 was fused
with extracellular region of CTLA4 to generate HPVml6E7-eCTLA4 fusion protein. Binding of this fusion protein to B7 molecules
expressed on antigen presenting-cells (APCs) was demonstrated. C57BL/6 (H-2b) mice immunized with low dose of the fusion protein (10 μg) produced higher titer antibody and stronger specific CTL response,
and expressed higher levels of IFN-γ and IL-12, compared with those immunized with HPVml6E7 only or admixture of HPVml6E7
and CTLA4, or PBS; and were protected from lethal dose tumor challenge. Tumor growth was retarded and survival prolonged in
mouse models with the fusion protein treatment. Our results demonstrate that fusion of HPV16 E7 with eCTLA4 targeting APCs
resulted in enhanced immunity, and that this fusion protein may be useful for improving the efficacy of immunotherapeutic
treatments of cervical cancer and other HPV16 infection-associated tumors. 相似文献
17.
The tumor-suppressing effects of SipB160/HPV16 E7 fusion protein, derived from human papillomavirus, and expressed in Salmonella enterica serovar typhimurium, were evaluated in a cervical cancer model. The expressed E7 protein resulted in efficacious cytotoxicity and tumor growth retardation in TC-1 cervical cancer cells. In addition, in mice bearing TC-1 tumors, live cells of Salmonella expressing HPV16 E7 were administered orally and induced immune responses through interferon-gamma and tumor necrosis factor-alpha cytokine secretion and also suppressed tumor growth (45 %) and prolonged survival (70 %) compared with the control group. These results suggested that the SipB160/HPV16 E7 fusion protein may be a candidate cancer therapeutic agent. 相似文献